Categories AlphaGraphs, Earnings, Health Care

Merck rises on oncology strength post Q2 earnings

Shares of pharmaceutical giant Merck (NYSE: MRK) rose 3% before the market hours on Tuesday after the company reported second-quarter results that were far ahead of analysts’ expectations.  

Boosted by the strength of its cancer drugs, worldwide sales increased 12% to 11.8 billion, which surpassed the average analysts’ expectation of $10.96 billion.

Merck stock gained on reporting better-than expected Q2 2019 earnings

Sales of key oncology drug Keytruda jumped 58% to $2.63 billion, lifting the overall pharmaceutical sales up 13%.

International pharmaceutical sales represented 55% of total sales in the quarter. Performance in international markets was led by China, which had pharmaceutical sales of $745 million representing growth of 41%.

Earnings, excluding one-time items, grew 23% to $1.30 per share, 14 cents higher than the street view.

READ: Apple needs to clear many hurdles to push stock higher post Q3 earnings

Outlook

Merck raised its full-year 2019 revenue range to be between $45.2 billion and $46.2 billion. Meanwhile, it reduced its guidance for GAAP EPS range to between $3.78 and $3.88, to take into account charges related to the acquisition of Peloton.

Excluding one-time items, earnings for this period is expected between $4.84 and $4.94.

The stock has gained 27% in the trailing 52 weeks and 9% since the beginning of this year.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Also Read:  Yelp Q2 earnings: All key figures

Most Popular

Baidu (BIDU) Q2 earnings rise unexpectedly; stock falls

https://www.youtube.com/watch?v=50yUaLybUnA&t=667s China-based internet search firm Baidu Inc. (NASDAQ: BIDU) reported financial results for the second quarter of 2020 on Thursday after the market's close. Earnings exceeded analysts’ expectations, but the

Applied Materials (AMAT) tops Q3 2020 targets; provides Q4 outlook

Applied Materials' (NASDAQ: AMAT) earnings and revenue for the third quarter exceeded the market's views. Adjusted EPS of $1.06 and revenue of $4.40 billion in Q3, grew 43% and 23%,

Is Altimmune (ALT) stock a buy right now?

A lot of stocks in the biotech space have skyrocketed this year after their announcements and advances in finding a vaccine or in the treatment of COVID-19. While these companies

One thought on “Merck rises on oncology strength post Q2 earnings

Comments are closed.

Top